NTHI NeOnc Technologies Holdings Inc.

Execution in biotech doesn’t happen on one front. Recent progress at $NTHI has included positive NEO100 Phase 2a results, completion of NEO212 Phase 1 dose escalation, a $15M financing, and the elimination of potential dilution associated with its Series A Preferred Stock. Now, the appointment of Ali Alabedin adds decades of financial governance and international growth experience at the Board level. Clinical. Regulatory. Financial. Institutional. Different areas, one focus: building the capabilities to move the pipeline forward. $NTHI $RXRX $ABCL

CEO & President Heshmatpour Amir F bought $231K of $NTHI stock from Nov 5 to Nov 6. 70,000 shares.

$NTHI has signed an MoU with the Department of Health – Abu Dhabi, creating a framework for cooperation across CNS oncology research, clinical development capabilities, specialist training, and real-world evidence. The MoU builds on DoH IND clearances for both NEO100 and NEO212 and comes as two children in Abu Dhabi are receiving investigational NEO100 through Compassionate Care, with a third expected this week. The parties will also assess clinical trial opportunities and explore a potential regional presence for NeOnc in Abu Dhabi, subject to separate agreements and applicable approvals. From regulatory authorization to patient access and broader clinical collaboration, NeOnc’s presence in Abu Dhabi continues to expand.

$NTHI The main thing is that it works and saves lives and suffering These days I invest in start ups that are trying to help the world Here, IOVA, Rivian, EVgo, XE, CTVA

Differentiation can create opportunity—especially when it addresses a limitation existing approaches still face. NEO100 takes a differentiated approach to CNS drug delivery: non-invasive intranasal administration designed to deliver purified perillyl alcohol directly to the brain. As NEO100 advances, that delivery approach adds another layer to what makes the program worth watching. $NTHI $NVAX $RXRX

$NTHI have been digging into this heavily. What do we think possible TAM is? As of now mostly focused on Glioblastoma which is somewhat small, but still very real path to $2B+ valuation here with developments?

$NTHI "Insider Purchases: Following the Phase 2a results, Mr. Heshmatpour and Dr. Chen purchased a combined 160,016 shares of NeOnc common stock for approximately $629,000 in open-market transactions using personal funds."

$NTHI signed an MoU with Abu Dhabi's Department of Health to boost brain-cancer research collaboration.

$NTHI Why aren’t more people excited a iut this comoany and their ip oming meeting witrh the FDA on November 17? All indicarions are that the company has groundbreaking treatment for brain cancer and the only worry, albeit a big ine, is future financing

$NTHI secures boardroom firepower with new director appointment and redeems Series A preferred.